GSK 2981710

Drug Profile

GSK 2981710

Alternative Names: GSK2981710

Latest Information Update: 22 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Ketones; Nootropics; Triglycerides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cognition disorders; Memory disorders

Most Recent Events

  • 01 Jul 2015 GlaxoSmithKline completes a phase I trial in Cognition and Memory disorders in the United Kingdom (NCT01702480)
  • 01 Nov 2012 Phase-I clinical trials in Cognition disorders (in patients aged 55 to 80 years) in United Kingdom (PO)
  • 01 Nov 2012 Phase-I clinical trials in Memory disorders (in patients aged 55 to 80 years) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top